Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: A phase II trial

Annals of Surgical Oncology

Volumn 18, Issue 13, 2011, Pages 3615-3622

  Katz, Matthew H G ^a   Wolff, Robert ^a   Crane, Christopher H ^a   Varadhachary, Gauri ^a   Javle, Milind ^a   Lin, E ^a   Evans, Douglas B ^b   Lee, Jeffrey E ^a   Fleming, Jason B ^a   Pisters, Peter W T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MENTAL HEALTH; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; SIDE EFFECT; STOMATITIS; VALIDATION STUDY; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 82955203361     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1847-4     Document Type: Conference Paper

References (23)

1. MH Kalser SS Ellenberg 1985 Pancreatic cancer Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 120 899 903 1:STN:280:DyaL2M3ltFSnsQ%3D%3D
2. JH Klinkenbijl J Jeekel T Sahmoud, et al. 1999 Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group Ann Surg. 230 776 782 10615932 10.1097/00000658-199912000- 00006 1:STN:280:DC%2BD3c%2FotFKkug%3D%3D (Pubitemid 30191812)
3. H Oettle S Post P Neuhaus, et al. 2007 Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA. 297 267 277 17227978 10.1001/jama.297.3.267 1:CAS:528:DC%2BD2sXotVCmug%3D%3D (Pubitemid 46143304)
4. WF Regine KA Winter RA Abrams, et al. 2008 Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA. 299 1019 1026 18319412 10.1001/jama.299.9.1019 1:CAS:528:DC%2BD1cXjtVSltL0%3D (Pubitemid 351347058)
5. Y Nukui VJ Picozzi LW Traverso 2000 Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg. 179 367 371 10930481 10.1016/S0002-9610(00) 00369-X 1:STN:280:DC%2BD3cvitl2isA%3D%3D (Pubitemid 30621642)
6. VJ Picozzi RA Kozarek LW Traverso 2003 Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma Am J Surg. 185 476 480 12727570 10.1016/S0002-9610(03)00051-5 (Pubitemid 36513960)
7. A Ismail CJ Van Groeningen A Hardcastle, et al. 1998 Modulation of fluorouracil cytotoxicity by interferon-alpha and -gamma Mol Pharmacol. 53 252 261 9463483 1:CAS:528:DyaK1cXht12htrc%3D (Pubitemid 28099735)
8. EE Vokes 1994 The promise of biochemical modulation in combined modality therapy Semin Oncol. 21 29 33 7527598 1:STN:280:DyaK2M%2FosVaisA%3D%3D
9. S Wadler R Wersto V Weinberg, et al. 1990 Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects Cancer Res. 50 5735 5739 1697499 1:CAS:528:DyaK3cXmtVCmsbc%3D (Pubitemid 20331368)
10. JE Byfield P Calabro-Jones I Klisak, et al. 1982 Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or FTORAFUR and X rays Int J Radiat Oncol Biol Phys. 8 1923 1933 6818194 10.1016/0360-3016(82)90451-5 1:CAS:528:DyaL3sXhtVels7g%3D (Pubitemid 13167377)
11. LR Holsti K Mattson A Niiranen, et al. 1987 Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung Int J Radiat Oncol Biol Phys. 13 1161 1166 3038802 10.1016/0360-3016(87)90189-1 1:STN:280:DyaL2s3nvFantg%3D%3D
12. VJ Picozzi RA Abrams PA Decker, et al. 2011 Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG trial Z05031 Ann Oncol. 22 348 354 20670978 10.1093/annonc/mdq384 1:STN:280: DC%2BC3M3htlGnuw%3D%3D
13. A Marten J Schmidt J Debus, et al. 2010 CapRI: final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-a2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC) J Clin Oncol 28 Suppl LBA4012
14. DC Linehan MC Tan SM Strasberg, et al. 2008 Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study Ann Surg. 248 145 151 18650621 10.1097/SLA.0b013e318181e4e9
15. Common terminology criteria for adverse events (CTCAE), version 3. Washington, DC: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2003.
16. NK Aaronson S Ahmedzai B Bergman, et al. 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst. 85 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D (Pubitemid 23073154)
17. MJ Hjermstad SD Fossa K Bjordal, et al. 1995 Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire J Clin Oncol. 13 1249 1254 7738629 1:STN:280:DyaK2M3ls12msg%3D%3D
18. D Fitzsimmons CD Johnson S George, et al. 1999 Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life Eur J Cancer. 35 939 941 10533475 10.1016/S0959-8049(99)00047-7 1:STN:280:DC%2BD3c%2FgtlKlug%3D%3D (Pubitemid 29277128)
19. L Radloff 1977 A new self report depression scale for research in the general population Appl Psychol Meas 1 385 401 10.1177/014662167700100306
20. RF Hwang H Wang A Lara, et al. 2008 Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer Ann Surg Oncol 15 1356 1366 18256882 10.1245/s10434-008-9833-1
21. MH Katz NB Merchant S Brower, et al. 2011 Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial Ann Surg Oncol 18 337 344 20811779 10.1245/s10434-010-1282-y
22. TA Aloia JE Lee JN Vauthey, et al. 2007 Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 204 347 355 17324767 10.1016/j.jamcollsurg.2006.12.011 (Pubitemid 46283494)
23. MC Posner WE Gooding RJ Landreneau, et al. 1998 Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction Cancer J Sci Am. 4 237 246 9689982 1:STN:280:DyaK1czlsVCgtA%3D%3D